Sumanta K. Pal, MD, on Advanced RCC: Tivozanib to Treat Disease Progression After Axitinib
2021 Genitourinary Cancers Symposium
Sumanta K. Pal, MD, of City of Hope, discusses findings of the TIVO-3 study, which showed that the tyrosine kinase inhibitor tivozanib improved progression-free survival vs sorafenib in patients whose advanced renal cell carcinoma progressed after multiple lines of therapy (Abstract 278).
Tracy L. Rose, MD, of the University of North Carolina at Chapel Hill, discusses phase II results of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy prior to radical cystectomy for patients with muscle-invasive bladder cancer. The trial showed this combination treatment is generally safe and may improve pathologic downstaging, but further study is warranted (Abstract 396).
Thomas Powles, MD, PhD, of Cancer Research UK Barts Centre, discusses phase III results from the EV-301 trial, which showed that enfortumab vedotin is the first therapy to demonstrate a significant survival advantage over standard chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma (Abstract 393).
Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses key abstracts discussed at this year’s meeting on renal cell carcinoma and offers her views on the latest trends and findings (Abstracts 269, 308, 270, 313).
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses phase III results of the CLEAR study, which showed that for first-line treatment of advanced renal cell carcinoma, lenvatinib plus pembrolizumab improved outcomes vs sunitinib. Lenvatinib plus everolimus also improved progression-free survival and overall survival rates vs sunitinib (Abstract 269).
A spirited discussion ensued when we asked Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, and Thomas Powles, MD, PhD, of Cancer Research UK Barts Centre, to compare notes on how they treat bladder, prostate, and kidney cancers.